Neupro

Treatment for Parkinson's Disease, Restless Legs Syndrome

Update: Neupro Now FDA Approved - May 9, 2007

Schwarz Pharma Submits Marketing Applications for its Rotigotine Patch 'Neupro'

MONHEIM, Germany, September 29, 2004 - New Drug Application (NDA) and Marketing Authorization Application (MAA) for Neupro (rotigotine transdermal system) to treat Parkinson’s disease submitted to the U.S. and the European regulatory authorities for review.

Schwarz Pharma announced today that applications for marketing approval for the rotigotine transdermal system, a patch, to treat patients in early stages of Parkinson's disease have been submitted to both, the European Medicines Agency (EMEA) and the U.S. Food and Drug Administration (FDA).

Neupro, with the active ingredient rotigotine, is a novel dopamine receptor-agonist formulated as a continuous transdermal delivery system, a patch. The patch is applied once a day to the skin and administers rotigotine transdermally to the body for 24 hours. Multinational clinical studies with patients in early stages of Parkinson's disease were completed at the end of 2003. More than 1,500 patients with Parkinson’s disease have been treated with Neupro (rotigotine transdermal system) in 15 clinical trials.

"This is an important milestone for our company. We are a step closer delivering on our strategy – to develop and to market innovative drugs in the areas of neurology and urology", said Patrick Schwarz-Schütte, CEO Schwarz Pharma AG. "'Neupro' has been proposed as the worldwide brand name for our patch."

"This is the first submission of a novel new chemical entity from our innovative pipeline," Iris Loew-Friedrich, MD, PhD, Member of the Executive Board Schwarz Pharma AG said. "The rotigotine team has worked diligently to bring the project to this significant achievement. With many advanced clinical development projects in our pipeline, we are looking forward to the NDA and MAA submissions to come."

Parkinson’s disease is a disorder of the central nervous system. The patients - roughly four million worldwide - suffer from a lack of dopamine, a messenger substance in the central nervous system, which is responsible for the co-ordination of movement. As a result of this shortage, patients are no longer able to control their movements reliably. Dopamine agonists attempt to compensate for this lack of dopamine.

Schwarz Pharma develops innovative drugs with focus on neurology and urology. There are currently seven projects in clinical development. Also in the last stage of development, phase III are harkoseride to treat epilepsy and neuropathic pain and fesoterodine for the treatment of urinary incontinence. Rotigotine transdermal system is also being studied in phase III trials for treatment of advanced stages of Parkinson's disease and Restless Legs Syndrome (RLS).

Schwarz Pharma AG (headquartered in Monheim, Germany) develops and markets innovative drugs for unmet medical needs with focus on neurology, urology and cardiovascular diseases. The company is investing in development projects targeting diseases such as Parkinson's disease, Restless-Legs-Syndrome, epilepsy, neuropathic pain, overactive bladder syndrome and benign prostatic hyperplasia. The company has a strong international presence with subsidiaries in Europe, USA and Asia. Shares of Schwarz Pharma AG are traded on the Frankfurt and Duesseldorf stock exchanges.

For more information, please visit www.schwarzpharma.com

Posted: September 2004

Related Articles

Neupro (rotigotine) FDA Approval History

View comments

Hide
(web5)